drugset / Trial / NCT07425483
CAR-NK Cells (CL-NK-003) in Pancreatic Cancer
Phase 1
Recruiting
9 enrolled
Changhai Hospital
National Key Laboratory of Immunity and Inflammation · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label, first-in-human, fixed-dose study in patients with pancreatic cancer.
Timeline
- Start
- 2026-02-12
- Primary completion
- 2026-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CL-NK-003 | Cell therapy | 3e+09 cells | — |